This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Hydrogen energy industry policy: warm wind blows the industrial chain; listed companies accelerate to enter the new track
Declaration of the first affordable rental housing REITs
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Another Chinese EV Startup Turns Profitable in China’s RMB 5 Trillion Auto Market
May 06, 2026 12:05 PM
AIFC Governor Renat Bekturov: Kazakhstan Is the Gateway for Chinese Capital Moving West
Apr 30, 2026 03:33 PM